Evidence map›Paper›PMID 22384045›Full record

ArticlePloS one2012

Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response.

Elizabeth Richardson, Simon R Stockwell, He Li, Wynne Aherne, Maria Emanuela Cuomo, Sibylle Mittnacht

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting PRPK Function Blocks Colon Cancer Metastasis.Molecular cancer therapeutics · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elizabeth RichardsonDepartment of Cancer Biology, UCL Cancer Institute, London, United Kingdom.
Simon R Stockwell
He Li
Wynne Aherne
Maria Emanuela Cuomo
Sibylle Mittnacht
Institute of Cancer Research · GBCRUK Lung Cancer Centre of Excellence · GB

Funding

Cancer Research UK CRC278XCancer Research UK CRM048
6 · The paper itself

Abstract

DNA damage activates checkpoint controls which block progression of cells through the division cycle. Several different checkpoints exist that control transit at different positions in the cell cycle. A role for checkpoint activation in providing resistance of cells to genotoxic anticancer therapy, including chemotherapy and ionizing radiation, is widely recognized. Although the core molecular functions that execute different damage activated checkpoints are known, the signals that control checkpoint activation are far from understood. We used a kinome-spanning RNA interference screen to delineate signalling required for radiation-mediated retinoblastoma protein activation, the recognized executor of G(1) checkpoint control. Our results corroborate the involvement of the p53 tumour suppressor (TP53) and its downstream targets p21(CIP1/WAF1) but infer lack of involvement of canonical double strand break (DSB) recognition known for its role in activating TP53 in damaged cells. Instead our results predict signalling involving the known TP53 phosphorylating kinase PRPK/TP53RK and the JNK/p38MAPK activating kinase STK4/MST1, both hitherto unrecognised for their contribution to DNA damage G1 checkpoint signalling. Our results further predict a network topology whereby induction of p21(CIP1/WAF1) is required but not sufficient to elicit checkpoint activation. Our experiments document a role of the kinases identified in radiation protection proposing their pharmacological inhibition as a potential strategy to increase radiation sensitivity in proliferating cancer cells.

Indexed as

DNA DamageG1 PhaseAntineoplastic AgentsCell CycleCell Line, TumorCell SurvivalCyclin-Dependent Kinase Inhibitor p21Gene Expression Regulation, NeoplasticGenes, ReporterGreen Fluorescent ProteinsHumansMAP Kinase Kinase 4Models, GeneticRNA InterferenceSignal TransductionTumor Suppressor Protein p53Antineoplastic AgentsCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Green Fluorescent ProteinsMAP Kinase Kinase 4TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID22384045
PMCPMC3288045
OpenAlexW1979743847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.